Grufity logo
Grufity logo

Latest ORBIMED ADVISORS LLC Stock Portfolio

$5.40Billion | No. of Holdings #117

Jonathan Silverstein Performance

2026 Q2+13.77%
YTD+12.34%
2025+19.31%

About Jonathan Silverstein and 13F Hedge Fund Stock Holdings

Jonathan Silverstein is a hedge fund based in New York, NY. On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Jonathan Silverstein reported an equity portfolio of $5.4 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Jonathan Silverstein are EWTX, , LLY. The fund has invested 11.7% of it's portfolio in EDGEWISE THERAPEUTICS INC and 6.4% of portfolio in ENLIVEN THERAPEUTICS INC. <br><br> The fund managers got completely rid off MYRIAD GENETICS INC (MYGN), PFIZER INC (PFE) and DANAHER CORP DEL (DHR) stocks. They significantly reduced their stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), BICARA THERAPEUTICS INC and JANUX THERAPEUTICS INC (JANX). Jonathan Silverstein opened new stock positions in UNITEDHEALTH GROUP INC (UNH), ASCENDIS PHARMA A/S and HUMANA INC (HUM). The fund showed a lot of confidence in some stocks as they added substantially to SAVARA INC (SVRA), COGENT BIOSCIENCES INC (COGT) and IMAGENEBIO INC (IKNA).
Jonathan Silverstein Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$5.40Billion
  as of Aug 14, 2026

Jonathan Silverstein Annual Return Estimates Vs S&P 500

Our best estimate is that ORBIMED ADVISORS LLC made a return of 13.77% in the last quarter. In trailing 12 months, it's portfolio return was 46.52%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
unitedhealth group inc66,958,000
ascendis pharma a/s65,201,300
humana inc65,183,800
odyssey therapeutics inc56,152,400
arcutis biotherapeutics inc53,541,200
west pharmaceutical svsc inc25,345,400
aura biosciences inc23,666,700
spyre therapeutics inc16,526,000
New stocks bought by ORBIMED ADVISORS LLC

Additions

Ticker% Inc.
savara inc523
cogent biosciences inc421
imagenebio inc140
kiniksa pharmaceuticals intl132
bright minds biosciences inc132
ataibeckley inc129
palvella therapeutics inc ne117
traws pharma inc98.71
Additions to existing portfolio by ORBIMED ADVISORS LLC

Reductions

Ticker% Reduced
alnylam pharmaceuticals inc-85.71
bicara therapeutics inc-71.36
disc medicine inc-66.51
definium therapeutics inc-54.55
janux therapeutics inc-46.66
axsome therapeutics inc.-45.04
trevi therapeutics inc-41.73
boston scientific corp-37.74
ORBIMED ADVISORS LLC reduced stake in above stock

Sold off

Ticker$ Sold
myriad genetics inc-122,875,000
esperion therapeutics inc ne-28,962,600
heron therapeutics inc-7,854,530
vistagen therapeutics inc-1,748,790
pfizer inc-54,657,700
adc therapeutics sa-4,942,600
carlsmed inc-11,336,000
compass pathways plc-6,363,070
ORBIMED ADVISORS LLC got rid off the above stocks

Sector Distribution

ORBIMED ADVISORS LLC has about 59.7% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare59.7
Others39.1
1.3

Market Cap. Distribution

ORBIMED ADVISORS LLC has about 22.5% of it's portfolio invested in the large-cap and mega-cap stocks.

  • UNALLOCATED
  • MID-CAP
  • LARGE-CAP
  • SMALL-CAP
  • MEGA-CAP
  • MICRO-CAP
Category%
UNALLOCATED39.1
MID-CAP24.1
LARGE-CAP12.5
SMALL-CAP12.2
MEGA-CAP10
MICRO-CAP2.2

Stocks belong to which Index?

About 46.5% of the stocks held by ORBIMED ADVISORS LLC either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
  • S&P 500
Index%
Others53.5
RUSSELL 200028.8
S&P 50017.7
Top 5 Winners (%)%
QURE
uniqure nv
167.7 %
definium therapeutics inc
108.3 %
URGN
urogen pharma ltd
92.8 %
mbx biosciences inc
82.5 %
RVMD
revolution medicines inc
71.7 %
Top 5 Winners ($)$
EWTX
edgewise therapeutics inc
141.7 M
mbx biosciences inc
89.6 M
enliven therapeutics inc
85.1 M
LLY
eli lilly & co
69.2 M
QURE
uniqure nv
58.6 M
Top 5 Losers (%)%
CMPX
compass therapeutics inc
-58.6 %
NSPR
inspiremd inc
-57.0 %
ONTX
traws pharma inc
-46.8 %
AORT
artivion inc
-37.0 %
BSX
boston scientific corp
-25.9 %
Top 5 Losers ($)$
CMPX
compass therapeutics inc
-47.2 M
BSX
boston scientific corp
-38.8 M
upstream bio inc
-11.8 M
ISRG
intuitive surgical inc
-11.6 M
astrazeneca plc
-8.2 M

Jonathan Silverstein Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Jonathan Silverstein

ORBIMED ADVISORS LLC has 117 stocks in it's portfolio. About 42.1% of the portfolio is in top 10 stocks. CMPX proved to be the most loss making stock for the portfolio. EWTX was the most profitable stock for ORBIMED ADVISORS LLC last quarter.

$5.28BTotal Value
141Positions
14 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of Jonathan Silverstein, last reported on 14 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ADCT
Adc Therapeutics Sa

Adc Therapeutics Sa

ADCT
Jonathan Silverstein's holding in Adc Therapeutics Sa over time
0%0.00
$0.00
0%
decreased 100 percentsold off
ARGX
Argenx Se

Argenx Se

ARGX
Jonathan Silverstein's holding in Argenx Se over time
1.6%92,880
$86.17M
1.6%
decreased 32.15 percentreduced
ASND
Ascendis Pharma A/S

Ascendis Pharma A/S

ASND
Jonathan Silverstein's holding in Ascendis Pharma A/S over time
0%0.00
$0.00
0%
decreased 100 percentsold off